Léčba AL-amyloidózy - výsledky jednoho pracoviště a přehled publikovaných zkušeností s novými léky (bortezomibem, thalidomidem a lenalidomidem) u AL-amyloidózy

Investor logo

Warning

This publication doesn't include Faculty of Education. It includes Faculty of Medicine. Official publication website can be found on muni.cz.
Title in English Treatment of AL-amyloidosis-results from one clinic and review of published experience with new agents (bortezomib, thalidomide and lenalidomide) in AL-amyloidosis
Authors

ADAM Zdeněk POUR Luděk KREJČÍ Marta ZAHRADOVÁ Lenka KŘIVANOVÁ Andrea ŠMARDOVÁ Jana KOVÁŘOVÁ Lenka ŠTĚPÁNKOVÁ Soňa MOULIS Mojmír KŘEN Leoš VESELÝ Karel SVOBODOVÁ Iva ČERMÁKOVÁ Zdeňka NEDBÁLKOVÁ Marta MAYER Jiří HÁJEK Roman

Year of publication 2010
Type Article in Periodical
Magazine / Source Vnitřní lékařství
MU Faculty or unit

Faculty of Medicine

Citation
Field Oncology and hematology
Keywords AL-amyloidosis;monoclonal gammopathy; light chain deposition disease; thalidomide; bortezomib; nephortic syndrome
Description 15 patients with light chain deposits in the form of AL-amyloidosis and 2 patients with light chain deposition as amorphous matter (light chain deposition disease) were treated at our clinic as of 1999. Combination of thal, dexamethasone and cyclophosphamide (CTD) was used in 4 patients. Treatment combination of Velcade, cyclophosphamide and dexamethasone (VCD) was used in 3 patients. In one patient (6 completed CTD cycles with the PR result) this combination led to complete haematological remission, complete remission was also achieved in the second patient and the application of 2 CVD cycles led to CR in the third (5 CTD cycles with PR result). Just one of the 3 female patients has been followed up for more than 12 months and so it is possible to evaluate organ treatment response in this patient; nephrotic syndrome ceased, meaning that organ CR has been achieved. Early diagnosis enables administration of aggressive treatment with the outlook of complete haematological and organ treatment response.
Related projects:

You are running an old browser version. We recommend updating your browser to its latest version.